Mizuho lowered the firm’s price target on CVS Health (CVS) to $66 from $73 and keeps an Outperform rating on the shares. The firm cut estimates following last week’s preannouncement. The analyst believes the company’s medical loss ratio trends are likely to improve in 2025 due to start payments, but expects the MLR to remain elevated from 2023 baselines.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: